

<p>IN THIS ISSUE:</p> <ul style="list-style-type: none"> Publicly Funded Rotavirus Vaccine Product Change 	<p>FROM: Lawrence Loh, MD, MPH, FCFP, FRCPC, FACPM Medical Officer of Health</p>
---	---

Publicly Funded Rotavirus Vaccine Product Change

Ontario’s Ministry of Health has advised that the infant rotavirus vaccine program will transition from **RotaTeq®** to **Rotarix®** resulting from the federal vaccine bulk purchasing program.

Infants born on or after June 1, 2021 should start a 2-dose rotavirus vaccine series given at 2 months and 4 months of age with **Rotarix®**. This cohort will initiate their series in August 2021.

Depending on supply, RotaTeq® may not be available beyond Fall 2021. NACI recommends that a vaccine series should be started and completed with the **same product whenever possible**.

Additional information for health care providers is available at: <https://www.peelregion.ca/health/professionals/pdfs/2021/Rotarix-hcp-transition-qa.pdf>

The Rotarix® Product Monograph is available at: <https://ca.gsk.com/media/1216129/rotarix.pdf>

Scenarios to Complete Rotavirus Vaccine Series:

Scenario	Response
1 or 2 doses of RotaTeq® given and RotaTeq® is available	Complete 3-dose series with RotaTeq® at an interval of 4 to 10 weeks between each dose. All doses should be administered by 32 weeks of age.
1 st dose of RotaTeq® was given and RotaTeq® is not available	Complete series with 2 doses of Rotarix® at an interval of 4 weeks between doses. Two doses should be completed by <25 weeks of age.
2 doses of RotaTeq® was given and RotaTeq® is not available	Complete series with 1 dose of Rotarix® by <25 weeks of age.
If product is unknown for the 1 st dose (e.g., from out of province with an immunization record that does not specify which rotavirus vaccine was received)	Complete series with 2 doses of Rotarix® vaccine. Two doses should be completed by <25 weeks of age.

Rotarix® by GlaxoSmithKline Inc.	RotaTeq® by Merck Canada Inc.
<ul style="list-style-type: none"> Live, attenuated, monovalent (Rot-1) 1.5 mL oral dose 2 doses, given at least 4 weeks apart Routinely given at 2 and 4 months of age First dose can be administered as early as 6 weeks of age. Administration of the 2 doses should be completed by <25 weeks of age. 	<ul style="list-style-type: none"> Live, attenuated, pentavalent (Rot-5) 2.0 mL oral dose 3 doses, given at least 4 to 10 weeks apart Routinely given at 2, 4 and 6 months of age First dose can be administered as early as 6 weeks of age. Completion of the 3rd dose by 32 weeks of age.

Vaccine orders can be submitted online at:

<https://peelregion.ca/health/professionals/V-07-629.htm>

For publicly funded immunization program related questions, contact the Immunization Policy and Programs Unit at: vaccine.program@ontario.ca.